Foralumab

Foralumab is a fully human monoclonal antibody that binds to CD3 epsilon.[1] Also called TZLS-401, it is currently in clinical development by Tiziana Life Sciences for treatment of Crohn's disease and other autoimmune diseases.[2] However foralumab did not show efficacy for Crohn's disease.[3]

Foralumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetCD3 epsilon
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
 ☒NcheckY (what is this?)  (verify)

It is currently in clinical development by Tiziana Life Sciences for treatment of secondary progressive Multiple sclerosis.[4][5]

References

  1. World Health Organization (2010). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 103" (PDF). WHO Drug Information.
  2. "Foralumab". Tiziana Life Sciences plc.
  3. Giuffrida P, Di Sabatino A (September 2020). "Targeting T cells in inflammatory bowel disease". Pharmacological Research. 159: 105040. doi:10.1016/j.phrs.2020.105040. PMID 32585338. S2CID 220073839.
  4. Wexler M. "2nd SPMS Patient Sees Clinical Gains With Foralumab Treatment". Multiple Sclerosis News Today. Retrieved 16 June 2022.
  5. "Intranasal Foralumab Provides Neuroimaging and Clinical Improvements in Secondary Progressive Multiple Sclerosis". practicalneurology. Retrieved 6 August 2022.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.